Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Rallybio Corporation  (NASDAQ:RLYB) shares are up Monday following a merger agreement with Candid Therapeutics Inc.This news has generated excitement among investors as the combined company aims to advance a leading portfolio of T-cell engager therapeutics for autoimmune diseases, adding momentum to the stock’s performance.MergerThe merger will see Rallybio acquire Candid, which has secured over $505 million in financing from a syndicate of leading healthcare institutional investors. Pro-forma cash of appro ...